Skip to main content Skip to section navigation Skip to footer
SCYNEXIS, Inc. SCYNEXIS, Inc.
  • About Us
    • Our Mission
    • Leadership
    • Partnerships
    • Careers
    • Contact Us
  • Our Science
    • Ibrexafungerp
    • Life-threatening Infections
    • Community Infections
    • Pipeline
    • Publications and Presentations
  • Our Product
  • News
    • News
    • Events
  • Careers
  • Investors
    • News & Events
    • Company Info
    • Financial Info
    • Stock Info
    • SEC Filings
    • Governance

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
    • Tear Sheet
  • Financial Info
    • Overview
    • Financial Results
    • Key Ratios
    • Investor Calculator
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Investor Calculator
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
    • Quarterly Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Dec 15, 2021 8:30am EST

European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS’ Innovative Antifungal Ibrexafungerp for the Indication of Invasive Candidiasis

Dec 06, 2021 7:00am EST

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

Dec 03, 2021 4:30pm EST

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 03, 2021 8:43am EST

SCYNEXIS Reports the Exercise of Warrants Totalling $7.9 Million

Dec 01, 2021 10:37am EST

BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of What’s New Award in the Health Category

Nov 29, 2021 8:30am EST

SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6

Nov 23, 2021 8:30am EST

SCYNEXIS Pivotal Phase 3 VANISH-306 Trial Results Published in the International Journal of Obstetrics and Gynaecology (BJOG) Demonstrate Statistical Superiority of BREXAFEMME® (Ibrexafungerp Tablets) Over Placebo for Vaginal Yeast Infection

Nov 10, 2021 7:34am EST

SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Nov 09, 2021 8:30am EST

SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp

Nov 03, 2021 8:30am EDT

SCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 33
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Scynexis
1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
Facebook Twitter Linkedin
  • Patents
  • Expanded Access
  • Privacy Policy
  • Disclaimer
  • Sitemap
© 2023 SCYNEXIS, Inc. All Rights Reserved.